<DOC>
	<DOCNO>NCT01613820</DOCNO>
	<brief_summary>Ketamine infusion result acute reduction global depression score severity suicidal ideation . Scopolamine infusion produce also significant improvement depression sustain time . We therefore plan investigate feasibility efficacy open-label repeat intravenous administration ketamine scopolamine combine population severely depressed , treatment-resistant patient . The result study could lead development new strategy treatment patient TRD .</brief_summary>
	<brief_title>Ketamine Scopolamine Infusions Treatment-resistant Major Depressive Disorder</brief_title>
	<detailed_description>Patients undergo two week prospective observation , receive IV infusion ketamine , scopolamine per randomization augmentation ongoing antidepressant regime . The schedule administration twice week three week . After phase subject follow assessment every two week three month .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Ketamine</mesh_term>
	<mesh_term>Scopolamine Hydrobromide</mesh_term>
	<mesh_term>Butylscopolammonium Bromide</mesh_term>
	<criteria>Outpatients sever treatmentresistant depression Currently depress Currently regular psychiatric care On aggressive antidepressant regimen , stable 4 week No history major psychiatric illness , include bipolar disorder No history psychosis No history drug abuse No major medical illness unstable medical condition .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>